The precise mechanistic underpinnings of KRAS pathway interactions with other known driver mutations in cutaneous melanoma remain insufficiently elucidated, warranting a deeper investigation into whether KRAS-associated gene dysregulation confers survival disadvantages or heightened metastatic capacity (15). The gene discussed is KRAS; the disease is cutaneous melanoma.